Rising incidence of breast cancer is fueling the demand for breast biopsy devices. Additionally, the growing awareness about the importance of early detection and increasing government initiatives for breast cancer screening are driving the market growth.
Technological advancements in breast biopsy devices, such as the development of automated and vacuum-assisted biopsy systems, are enhancing the accuracy and efficiency of procedures. This is expected to boost the adoption of these devices and drive market growth.
Increasing healthcare expenditure and growing investment in research and development activities in the field of breast cancer diagnosis are also contributing to the growth of the breast biopsy devices market.
Industry
Report Coverage | Details |
---|---|
Segments Covered | Product, Technique, End-Use |
Regions Covered | • North America (United States, Canada, Mexico) • Europe (Germany, United Kingdom, France, Italy, Spain, Rest of Europe) • Asia Pacific (China, Japan, South Korea, Singapore, India, Australia, Rest of APAC) • Latin America (Argentina, Brazil, Rest of South America) • Middle East & Africa (GCC, South Africa, Rest of MEA) |
Company Profiled | Stryker Boston Scientific FUJIFILM Holdings Argon Medical Devices, Inc Hologic Inc Cook Group Incorporated Becton, Dickinson and Company (BD) Medtronic plc Olympus Cardinal Health INRAD Inc Danaher B. Braun Melsungen AGS |
High cost associated with breast biopsy procedures and devices is a major restraint for market growth. The limited reimbursement coverage for these procedures in certain regions further hinders market expansion.
Stringent regulatory requirements for the approval of breast biopsy devices pose a challenge for market players. The lengthy and complex regulatory processes can delay product launches and limit market growth opportunities.